ClinicalTrials.Veeva

Menu

Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma

National Taiwan University logo

National Taiwan University

Status

Unknown

Conditions

Neuroblastoma

Study type

Observational

Funder types

Other

Identifiers

NCT01943097
200703053M

Details and patient eligibility

About

Neuroblastic tumors are childhood neoplasms that possess amino acid decarboxylase (AADC) activity and Meta-iodobenzylguanidine(MIBG), they can theoretically be imaged by (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) and (123)I-Meta-iodobenzylguanidine((123)I-MIBG) PET, they are new and specific diagnostic and follow-up tools for neuroendocrine tumors. In this study, we explored the accuracy and clinical role of (18)F-FDOPA and (123)I-MIBG PET in neuroblastic tumors.

METHODS:

Patients with tissue-proven neuroblastic tumors receiving (18)F-FDOPA PET or (123)I-MIBG at initial diagnosis or during follow-ups were enrolled. The sensitivity and specificity of (18)F-FDOPA or (123)I-MIBG PET were compared to each other and compared to(18)F-FDG PET, using tumor histology as the standard.

Enrollment

160 estimated patients

Sex

All

Ages

Under 30 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • (1) Diagnosed by clinical criteria(one of below)

    1. Proved as Neuroblastoma by a pathological section
    2. Bone meta with 24 hrs urine VMA(Vanillylmandelic acid )or HVA (Homovanillic acid) elevated
    3. CT or MRI found tumor around adrenal gland or Neuroblastic tumor
  • (2) Age between 0-30 years old,Body weight over 2.5kg

  • (3) Signed Inform Consent Form

Exclusion criteria

  • (1)AST and ALT > 200U/L、Cre > 2.5mg/dl
  • (2)Allerg to 18F-dopa、123I-MIBG
  • (3)Subject not fit this study(assessed by PI)
  • (4)No more need to arrenge PET because disease progress, assessed by VS

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems